Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$120,000.00

Metabolic impact of weight-loss drugs and kidney GDF15

EF 2024-25

Résumé
Obesity is a metabolic disorder that affects nearly one billion people globally. Clinically it is defined as having a body mass index equal to or greater than 30 kg/m², and is strongly associated with type 2 diabetes, cardiovascular disease and other comorbidities. With an estimated prevalence of 25% and 28% in Canadian women and men, respectively, there is a need to address this epidemic with urgency. Despite major advancements in weight-loss therapies, like glucagon-like peptide 1 receptor agonists (ie. semagltuide), which now provide viable treatment alternatives to bariatric surgery, the mechanism of action for these drugs remains to be fully elucidated. Recently, metformin the most heavily prescribed type 2 diabetic drug in the world, has been shown to stimulate a stress hormone known as growth differentiation factor 15 (GDF15) in the kidney to reduce feeding, weight, improve insulin sensitivity and lower blood sugar levels. However, the mechanism by which the kidney produces GDF15 in the context of metformin administration is not known. I aim to address this by using a variety of approaches, in-vivo, to silence and activate the expression of genes in the kidney that I think are responsible for producing GDF15, I will assess through these bi-directional changes if they are necessary and sufficient to reduce feeding and promote weight-loss in both obese male and female rats. Using similar approaches I will also investigate if semaglutide mediated weight loss and feeding reduction functions through GDF15. This project will dissect sex-dependent kidney mechanisms of metformin and semaglutide that potentially enhance GDF15 synthesis and action to regulate feeding and weight, thereby potentially unveiling novel therapeutic targets in the kidney to lower weight.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
518282
Name
Garrido Ameth-Nicholas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Metabolic impact of weight-loss drugs and kidney GDF15
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Area Postrema; Gastric Surgery; Gdf15; Gfral; Ivgtt; Metformin; Retrograde Ureteral Delivery Protocol; Semaglutide; Stereotaxic Brain Surgery; Upper Small Intestine Surgery
Abstract
Obesity is a metabolic disorder that affects nearly one billion people globally. Clinically it is defined as having a body mass index equal to or greater than 30 kg/m², and is strongly associated with type 2 diabetes, cardiovascular disease and other comorbidities. With an estimated prevalence of 25% and 28% in Canadian women and men, respectively, there is a need to address this epidemic with urgency. Despite major advancements in weight-loss therapies, like glucagon-like peptide 1 receptor agonists (ie. semagltuide), which now provide viable treatment alternatives to bariatric surgery, the mechanism of action for these drugs remains to be fully elucidated. Recently, metformin the most heavily prescribed type 2 diabetic drug in the world, has been shown to stimulate a stress hormone known as growth differentiation factor 15 (GDF15) in the kidney to reduce feeding, weight, improve insulin sensitivity and lower blood sugar levels. However, the mechanism by which the kidney produces GDF15 in the context of metformin administration is not known. I aim to address this by using a variety of approaches, in-vivo, to silence and activate the expression of genes in the kidney that I think are responsible for producing GDF15, I will assess through these bi-directional changes if they are necessary and sufficient to reduce feeding and promote weight-loss in both obese male and female rats. Using similar approaches I will also investigate if semaglutide mediated weight loss and feeding reduction functions through GDF15. This project will dissect sex-dependent kidney mechanisms of metformin and semaglutide that potentially enhance GDF15 synthesis and action to regulate feeding and weight, thereby potentially unveiling novel therapeutic targets in the kidney to lower weight.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Garrido, Ameth-Nicholas
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~